Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.

Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ.

Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30949-7. doi: 10.1016/j.eururo.2018.11.045. [Epub ahead of print]

PMID:
30553611
2.

Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer.

Hanna GJ, Kacew A, Chau NG, Shivdasani P, Lorch JH, Uppaluri R, Haddad RI, MacConaill LE.

JCI Insight. 2018 Sep 6;3(17). pii: 122799. doi: 10.1172/jci.insight.122799. eCollection 2018 Sep 6.

3.

Endometrial cancer with an EML4-ALK rearrangement.

Craig JW, Quade BJ, Muto MG, MacConaill LE.

Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4). pii: a003020. doi: 10.1101/mcs.a003020. Print 2018 Aug.

4.

Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma.

Papke DJ Jr, Nowak JA, Yurgelun MB, Frieden A, Srivastava A, Lindeman NI, Sholl LM, MacConaill LE, Dong F.

Mod Pathol. 2018 Dec;31(12):1882-1890. doi: 10.1038/s41379-018-0091-x. Epub 2018 Jun 28.

PMID:
29955144
5.

Frameshift events predict anti-PD-1/L1 response in head and neck cancer.

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI.

JCI Insight. 2018 Feb 22;3(4). pii: 98811. doi: 10.1172/jci.insight.98811. eCollection 2018 Feb 22.

6.

Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing.

MacConaill LE, Burns RT, Nag A, Coleman HA, Slevin MK, Giorda K, Light M, Lai K, Jarosz M, McNeill MS, Ducar MD, Meyerson M, Thorner AR.

BMC Genomics. 2018 Jan 8;19(1):30. doi: 10.1186/s12864-017-4428-5.

7.

Somatic mutations in CDH1 and CTNNB1 in primary carcinomas at 13 anatomic sites.

Busch EL, Hornick JL, Umeton R, Albayrak A, Lindeman NI, MacConaill LE, Garcia EP, Ducar M, Rebbeck TR.

Oncotarget. 2017 Sep 21;8(49):85680-85691. doi: 10.18632/oncotarget.21115. eCollection 2017 Oct 17.

8.

Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.

Garcia EP, Minkovsky A, Jia Y, Ducar MD, Shivdasani P, Gong X, Ligon AH, Sholl LM, Kuo FC, MacConaill LE, Lindeman NI, Dong F.

Arch Pathol Lab Med. 2017 Jun;141(6):751-758. doi: 10.5858/arpa.2016-0527-OA. Epub 2017 Mar 3.

PMID:
28557599
9.

Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.

Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF, Schumacher SE, O'Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A, Bi WL, Chang MS, Yang E, Wright KD, Manley PE, Ducar M, Alexandrescu S, Lidov H, Delalle I, Goumnerova LC, Church AJ, Janeway KA, Harris MH, MacConaill LE, Folkerth RD, Lindeman NI, Stiles CD, Kieran MW, Ligon AH, Santagata S, Dubuc AM, Chi SN, Beroukhim R, Ligon KL.

Neuro Oncol. 2017 Jul 1;19(7):986-996. doi: 10.1093/neuonc/now294.

10.

Institutional implementation of clinical tumor profiling on an unselected cancer population.

Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE.

JCI Insight. 2016 Nov 17;1(19):e87062. doi: 10.1172/jci.insight.87062.

11.

Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA.

Watkins JC, Howitt BE, Horowitz NS, Ritterhouse LL, Dong F, MacConaill LE, Garcia E, Lindeman NI, Lee LJ, Berkowitz RS, Nucci MR, Crum CP.

Mod Pathol. 2017 Mar;30(3):448-458. doi: 10.1038/modpathol.2016.187. Epub 2016 Nov 11.

12.

Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.

Ritterhouse LL, Nowak JA, Strickland KC, Garcia EP, Jia Y, Lindeman NI, Macconaill LE, Konstantinopoulos PA, Matulonis UA, Liu J, Berkowitz RS, Nucci MR, Crum CP, Sholl LM, Howitt BE.

Mod Pathol. 2016 Aug;29(8):893-903. doi: 10.1038/modpathol.2016.82. Epub 2016 May 6.

13.

KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.

Hwang DH, Sholl LM, Rojas-Rudilla V, Hall DL, Shivdasani P, Garcia EP, MacConaill LE, Vivero M, Hornick JL, Kuo FC, Lindeman NI, Dong F.

J Thorac Oncol. 2016 Apr;11(4):496-503. doi: 10.1016/j.jtho.2016.01.010. Epub 2016 Jan 30.

14.

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.

Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA.

JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5689. [Epub ahead of print]

PMID:
26822149
15.

Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality.

MacConaill LE, Lindeman NI, Rollins BJ.

JAMA Oncol. 2015 Oct;1(7):879-80. doi: 10.1001/jamaoncol.2015.1540. No abstract available.

PMID:
26181886
16.

MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.

Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovée JV, Patel B, Badalian-Very G, van Hummelen P, Ducar M, Lin L, MacConaill LE, Egeler RM, Rollins BJ.

Genes Chromosomes Cancer. 2015 Jun;54(6):361-8. doi: 10.1002/gcc.22247. Epub 2015 Mar 31.

PMID:
25899310
17.

Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women.

Chung TK, Van Hummelen P, Chan PK, Cheung TH, Yim SF, Yu MY, Ducar MD, Thorner AR, MacConaill LE, Doran G, Pedamallu CS, Ojesina AI, Wong RR, Wang VW, Freeman SS, Lau TS, Kwong J, Chan LK, Fromer M, May T, Worley MJ Jr, Esselen KM, Elias KM, Lawrence M, Getz G, Smith DI, Crum CP, Meyerson M, Berkowitz RS, Wong YF.

Int J Cancer. 2015 Aug 15;137(4):776-83. doi: 10.1002/ijc.29456. Epub 2015 Feb 13.

18.

BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers.

Abo RP, Ducar M, Garcia EP, Thorner AR, Rojas-Rudilla V, Lin L, Sholl LM, Hahn WC, Meyerson M, Lindeman NI, Van Hummelen P, MacConaill LE.

Nucleic Acids Res. 2015 Feb 18;43(3):e19. doi: 10.1093/nar/gku1211. Epub 2014 Nov 26.

19.

Novel genetic mutations in a sporadic port-wine stain.

Lian CG, Sholl LM, Zakka LR, O TM, Liu C, Xu S, Stanek E, Garcia E, Jia Y, MacConaill LE, Murphy GF, Waner M, Mihm MC Jr.

JAMA Dermatol. 2014 Dec;150(12):1336-40.

PMID:
25188413
20.

Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, Kluk M, Kuo F, Jia Y, Joshi R, Longtine J, Manning A, Palescandolo E, Sharaf N, Sholl L, van Hummelen P, Wade J, Wollinson BM, Zepf D, Rollins BJ, Lindeman NI.

J Mol Diagn. 2014 Nov;16(6):660-72. doi: 10.1016/j.jmoldx.2014.06.004. Epub 2014 Aug 23.

21.

Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.

Sadow PM, Priolo C, Nanni S, Karreth FA, Duquette M, Martinelli R, Husain A, Clohessy J, Kutzner H, Mentzel T, Carman CV, Farsetti A, Henske EP, Palescandolo E, Macconaill LE, Chung S, Fadda G, Lombardi CP, De Angelis AM, Durante O, Parker JA, Pontecorvi A, Dvorak HF, Fletcher C, Pandolfi PP, Lawler J, Nucera C.

J Natl Cancer Inst. 2014 Jul 25;106(8). pii: dju182. doi: 10.1093/jnci/dju182. Print 2014 Aug.

22.

Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.

Choy E, MacConaill LE, Cote GM, Le LP, Shen JK, Nielsen GP, Iafrate AJ, Garraway LA, Hornicek FJ, Duan Z.

PLoS One. 2014 Jul 1;9(7):e101283. doi: 10.1371/journal.pone.0101283. eCollection 2014.

23.

Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.

Kim YM, Lee SW, Chun SM, Kim DY, Kim JH, Kim KR, Kim YT, Nam JH, van Hummelen P, MacConaill LE, Hahn WC, Jang SJ.

PLoS One. 2014 Jun 17;9(6):e99451. doi: 10.1371/journal.pone.0099451. eCollection 2014.

24.

Somatic activating ARAF mutations in Langerhans cell histiocytosis.

Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovée JV, Tian SY, Van Hummelen P, Ducar M, MacConaill LE, Egeler RM, Rollins BJ.

Blood. 2014 May 15;123(20):3152-5. doi: 10.1182/blood-2013-06-511139. Epub 2014 Mar 20.

25.

Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency.

Hanna MC, Go C, Roden C, Jones RT, Pochanard P, Javed AY, Javed A, Mondal C, Palescandolo E, Van Hummelen P, Hatton C, Bass AJ, Chun SM, Na DC, Kim TI, Jang SJ, Osarogiagbon RU, Hahn WC, Meyerson M, Garraway LA, MacConaill LE.

PLoS One. 2013 Sep 16;8(9):e74950. doi: 10.1371/journal.pone.0074950. eCollection 2013.

26.

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.

Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS.

Cancer. 2013 Nov 1;119(21):3776-83. doi: 10.1002/cncr.28288. Epub 2013 Aug 23.

27.

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.

Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, Rich BE, Schumacher SE, McKenna A, Lawrence MS, Bergthold G, Brastianos PK, Tabak B, Ducar MD, Van Hummelen P, MacConaill LE, Pouissant-Young T, Cho YJ, Taha H, Mahmoud M, Bowers DC, Margraf L, Tabori U, Hawkins C, Packer RJ, Hill DA, Pomeroy SL, Eberhart CG, Dunn IF, Goumnerova L, Getz G, Chan JA, Santagata S, Hahn WC, Stiles CD, Ligon AH, Kieran MW, Beroukhim R, Ligon KL.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):8188-93. doi: 10.1073/pnas.1300252110. Epub 2013 Apr 30.

28.

Existing and emerging technologies for tumor genomic profiling.

MacConaill LE.

J Clin Oncol. 2013 May 20;31(15):1815-24. doi: 10.1200/JCO.2012.46.5948. Epub 2013 Apr 15. Review.

29.

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.

Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R.

Nat Genet. 2013 Mar;45(3):285-9. doi: 10.1038/ng.2526. Epub 2013 Jan 20.

30.

Advancing personalized cancer medicine in lung cancer.

MacConaill LE.

Arch Pathol Lab Med. 2012 Oct;136(10):1210-6.

PMID:
23020726
31.

Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors.

Kieran MW, Roberts CW, Chi SN, Ligon KL, Rich BE, Macconaill LE, Garraway LA, Biegel JA.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1155-7. doi: 10.1002/pbc.24315. Epub 2012 Sep 19.

32.

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.

Daniels AB, Lee JE, MacConaill LE, Palescandolo E, Van Hummelen P, Adams SM, DeAngelis MM, Hahn WC, Gragoudas ES, Harbour JW, Garraway LA, Kim IK.

Invest Ophthalmol Vis Sci. 2012 Oct 9;53(11):6991-6. doi: 10.1167/iovs.12-10427.

33.

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB, Garraway LA.

Cancer Discov. 2012 Jan;2(1):82-93. doi: 10.1158/2159-8290.CD-11-0184. Epub 2011 Nov 7.

34.

Integrating multiple social statuses in health disparities research: the case of lung cancer.

Williams DR, Kontos EZ, Viswanath K, Haas JS, Lathan CS, MacConaill LE, Chen J, Ayanian JZ.

Health Serv Res. 2012 Jun;47(3 Pt 2):1255-77. doi: 10.1111/j.1475-6773.2012.01404.x. Epub 2012 Mar 30.

35.

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA.

J Clin Oncol. 2012 Jan 20;30(3):316-21. doi: 10.1200/JCO.2011.36.7680. Epub 2011 Nov 7.

36.

Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges.

MacConaill LE, Van Hummelen P, Meyerson M, Hahn WC.

Cancer Discov. 2011 Sep;1(4):297-311. doi: 10.1158/2159-8290.CD-11-0110. Review.

37.

Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.

Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V, Goldman S, Taha H, Mahmoud M, Ozek M, Sav A, Longtine JA, Lindeman NI, Garraway LA, Ligon AH, Stiles CD, Santagata S, Chan JA, Kieran MW, Ligon KL.

J Mol Diagn. 2011 Nov;13(6):669-77. doi: 10.1016/j.jmoldx.2011.07.002. Epub 2011 Aug 30.

38.

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA.

J Clin Oncol. 2011 Aug 1;29(22):3085-96. doi: 10.1200/JCO.2010.33.2312. Epub 2011 Mar 7.

39.

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF.

BMC Cancer. 2011 Feb 8;11:60. doi: 10.1186/1471-2407-11-60.

40.

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, Macconaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, Krammer PH, Gülow K, Dummer R.

Blood. 2011 Feb 24;117(8):2433-40. doi: 10.1182/blood-2010-09-305128. Epub 2011 Jan 5.

41.

Clinical implications of the cancer genome.

Macconaill LE, Garraway LA.

J Clin Oncol. 2010 Dec 10;28(35):5219-28. doi: 10.1200/JCO.2009.27.4944. Epub 2010 Oct 25. Review.

42.

Recurrent BRAF mutations in Langerhans cell histiocytosis.

Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ.

Blood. 2010 Sep 16;116(11):1919-23. doi: 10.1182/blood-2010-04-279083. Epub 2010 Jun 2.

43.

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A.

J Transl Med. 2010 Apr 20;8:39. doi: 10.1186/1479-5876-8-39.

44.

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.

Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K.

Nat Med. 2010 Mar;16(3):286-94. doi: 10.1038/nm.2100. Epub 2010 Feb 14.

45.

Profiling critical cancer gene mutations in clinical tumor samples.

MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA.

PLoS One. 2009 Nov 18;4(11):e7887. doi: 10.1371/journal.pone.0007887. Erratum in: PLoS One. 2010;5(9). doi: 10.1371/annotation/613c7509-e4c9-42ac-82fb-fc504400d9e0. PLoS One. 2010;5(9). doi: 10.1371/annotation/3a0c8fee-57ef-43ed-b6c2-55b503e6db5e.

46.

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6. doi: 10.1073/pnas.0905833106. Epub 2009 Nov 13.

47.

Emi1 maintains genomic integrity during zebrafish embryogenesis and cooperates with p53 in tumor suppression.

Rhodes J, Amsterdam A, Sanda T, Moreau LA, McKenna K, Heinrichs S, Ganem NJ, Ho KW, Neuberg DS, Johnston A, Ahn Y, Kutok JL, Hromas R, Wray J, Lee C, Murphy C, Radtke I, Downing JR, Fleming MD, MacConaill LE, Amatruda JF, Gutierrez A, Galinsky I, Stone RM, Ross EA, Pellman DS, Kanki JP, Look AT.

Mol Cell Biol. 2009 Nov;29(21):5911-22. doi: 10.1128/MCB.00558-09. Epub 2009 Aug 24.

48.

Genome-wide functional synergy between amplified and mutated genes in human breast cancer.

Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, Dezso Z, Mulvey L, Macconaill LE, Winckler W, Serebryiskaya T, Nikolskaya T, Polyak K.

Cancer Res. 2008 Nov 15;68(22):9532-40. doi: 10.1158/0008-5472.CAN-08-3082.

49.

Toward accurate high-throughput SNP genotyping in the presence of inherited copy number variation.

Macconaill LE, Aldred MA, Lu X, Laframboise T.

BMC Genomics. 2007 Jul 3;8:211.

50.

Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583.

MacConaill LE, Hughes CM, Rozenblatt-Rosen O, Nannepaga S, Meyerson M.

Mol Cancer Res. 2006 Oct;4(10):793-801.

Supplemental Content

Loading ...
Support Center